Stereotactic Body Radiotherapy To Extend The Clinical Benefit Of Pd-1 Inhibitors In Recurrent/Metastatic Nasopharyngeal Carcinoma.
Y. Chen,Qiaojuan Guo,Jin Lin,Gang Chen,Leong Kin Pan,Yuqi Wang,Shaojun Lin,Mei Chen,Chuanben Chen,Lurong Zhang,Yunbin Ye,Jianping Lu,Jingfeng Zong,Tian Zhu Lu,Lina Tang,Li Zhang,Ya Lin,Fang Guo,Zeng-qing Guo,Jianji Pan
DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.e18013
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:e18013 Background: Emerging evidences have showed that immune checkpoint inhibitors lead to durable responses in a variety of advanced cancers, including recurrent/metastatic nasopharyngeal carcinoma(RM-NPC), however, combination approaches are required to extend this benefit beyond a subset of patients. This study retrospectively evaluated 9 RM-NPC patients, to investigate how stereotactic body radiationtherapy(SBRT) could potentiate programmed cell death protein 1(PD-1) checkpoint inhibition. Methods: Between September, 2016 and July, 2017, 9 consecutive RM-NPC cases were treated at our institution and Macau Clinics, for which prior standard therapy was ineffective(4 patients), had disease progression within 6 months of completion of definitive chemo-radiation(2 patients), or was considered inappropriate(3 patients), all except one received full-dose PD-1 inhibitors(either nivolumab or pembroizumab) combined with SBRT. Due to economic burden, most patients could not receive PD-1 inhibitors according to the recommended regimen of Food and Drug Administration. Treatment was discontinued as long as patients were experiencing clinical benefit in the opinion of the physicians and at least 5 cycles were given before stoppage. Results: After a median following-up time of 398 days, the confirmed objective response and complete responses rate based on RECIST1.1 was 88.9%(8/9) and 44.4%(4/9), respectively. The median progression free survival 1(PFS1) and PFS2 were 239 and 145 days, respectively, with the median overall survival(OS) was not reached at the time of censorship. Series biopsy was performed in patients with disease progression, we discovered that immune microenvironment, in terms of the expression amount and location of CD3, CD8, PD-1 and PD-L1, had not change significantly after drug resistance. Two in 9(22.2%) patients occurred grade 3~4 treatment-related adverse events(i.e. nausea and vomiting). Conclusions: PD-1 inhibitors combined with SBRT demonstrated promising antitumor activity and manageable safety profile in RM-NPC patients, and it may maximize clinical benefit beyond progression after PD-1 inhibitors treatment in a subset patients.